Jakhetiya Ashish, Kaul Priyanka, Meena Jitendra Kumar, Yadav Ajay Kumar, Tiwari Ajeet Ramamani, Kumar Rahul, Garg Pankaj Kumar
Department of Surgical Oncology, Geetanjali Medical College Hospital, Udiapur, India.
Department of General Surgery, Rama Medical College, Hapur, India.
Indian J Surg Oncol. 2025 Feb;16(1):103-108. doi: 10.1007/s13193-024-02040-7. Epub 2024 Jul 30.
This cross-sectional survey aimed to assess the knowledge and current practice of chemotherapy among breast surgeons in India. The objective was to evaluate their familiarity with chemotherapy protocols, treatment preferences, and utilisation of emerging technologies to identify areas for improvement and potential gaps in the delivery of breast cancer care. The survey employed a questionnaire-based approach using the Google Forms platform. A total of 264 breast surgeons actively involved in the clinical management of breast cancer participated in the study. The questionnaire consisted of 19 closed-ended questions covering various aspects of breast cancer management. The survey was distributed to participants via WhatsApp or email. The survey involved 264 surgeons, 60.6% employed at a cancer centre and 27.2% at a teaching hospital. A total of 43.1% reported routinely administering chemotherapy to patients with breast cancer, 32.8% took a selective approach, and 24.1% had never administered chemotherapy to breast cancer patients. In addition, 39.7% consistently discussed cases in a multidisciplinary team (MDT) setting, 24.8% preferred MDT discussions but not on every occasion, and 35.5% did not have access to an MDT. Regarding central venous access device (CVAD) utilisation, 10.3% always used CVADs, 67.2% used them selectively, and 22.4% did not routinely employ CVADs. Furthermore, 96.6% of respondents consistently inquired about molecular subtypes, while 53.4% advised patients about genetic testing. For management strategies, 86.2% considered NACT for selected EBC patients. The sandwich protocol was used for large operable breast cancer by 53.4%, and 58.6% used it for LABC. Only 36.2% considered SLNB in post-NACT cases, while 11.7% performed SLNB in this setting. These findings highlight the need for continued research, professional development training, consensus-building, and adherence to evidence-based guidelines to ensure optimal and standardised care for breast cancer patients in India.
这项横断面调查旨在评估印度乳腺外科医生对化疗的知识掌握情况和当前实践。目的是评估他们对化疗方案的熟悉程度、治疗偏好以及新兴技术的应用情况，以确定乳腺癌护理提供方面需要改进的领域和潜在差距。该调查采用基于问卷的方法，使用谷歌表单平台。共有264名积极参与乳腺癌临床管理的乳腺外科医生参与了这项研究。问卷包括19个封闭式问题，涵盖乳腺癌管理的各个方面。调查问卷通过WhatsApp或电子邮件分发给参与者。参与调查的有264名外科医生，其中60.6%受雇于癌症中心，27.2%受雇于教学医院。共有43.1%的人报告常规为乳腺癌患者进行化疗，32.8%采取选择性方法，24.1%从未为乳腺癌患者进行过化疗。此外，39.7%的人在多学科团队（MDT）环境中持续讨论病例，24.8%的人倾向于MDT讨论但并非每次都进行，35.5%的人无法参与MDT。关于中心静脉通路装置（CVAD）的使用，10.3%的人总是使用CVAD，67.2%的人选择性使用，22.4%的人不常规使用CVAD。此外，96.6%的受访者始终询问分子亚型，而53.4%的人建议患者进行基因检测。对于管理策略，86.2%的人考虑对选定的早期乳腺癌（EBC）患者进行新辅助化疗（NACT）。53.4%的人将夹心方案用于可手术的大型乳腺癌，58.6%的人将其用于局部晚期乳腺癌（LABC）。只有36.2%的人考虑在NACT后病例中进行前哨淋巴结活检（SLNB），而11.7%的人在此情况下进行了SLNB。这些发现凸显了持续开展研究、进行专业发展培训、建立共识以及遵循循证指南的必要性，以确保为印度的乳腺癌患者提供最佳和标准化的护理。
